SCHEDULE: Invus Group Acquires 6% Stake in Abivax S.A.

Several entities affiliated with Invus Group and Raymond Debbane have collectively acquired a 6.0% stake in Abivax S.A., signaling a notable investment in the biopharmaceutical company.

Summary

• Invus Public Equities, L.P. and its affiliated entities, along with Avicenna Life Sci Master Fund LP and its affiliates, have collectively reported beneficial ownership of 4,790,187 ordinary shares of Abivax S.A.
• This holding represents 6.0% of the total outstanding ordinary shares.
• The filing details the beneficial ownership structure, with Raymond Debbane having ultimate control over the aggregate holdings.
• The reporting date for this ownership stake is June 30, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, indicating a significant but not overwhelming stake acquisition by established investment entities, suggesting confidence in the company's future prospects without immediate aggressive control intentions.

Positives

• Acquisition of a significant 6.0% stake by established investment entities suggests confidence in Abivax S.A.'s potential.
• The clear reporting of ownership through a Schedule 13G indicates a transparent approach to disclosure by the reporting persons.
• The aggregate holding of 4,790,187 shares, comprising both ordinary shares and ADSs, demonstrates a substantial investment.

Negatives

• The filing does not contain any negative financial or operational information about Abivax S.A. itself, as it is a disclosure of ownership by third parties.

Risks

• Potential for future changes in ownership or investment strategy by the reporting persons could impact Abivax S.A.'s stock stability.
• While not explicitly stated as a risk in this filing, significant ownership by investment funds can sometimes lead to pressure for short-term financial performance.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Abivax S.A.

Management Comments

• Each of the Reporting Persons hereby makes the following certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.
• After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Industry Context

StockSavvy.ai notes that the acquisition of a significant stake in a biopharmaceutical company like Abivax S.A. by investment firms often reflects an assessment of the company's pipeline, clinical trial progress, or market potential within the biotechnology sector.

Stakeholder Impact

• Shareholders: The acquisition of a significant stake may influence market perception and potentially stock price, though the filing states the shares were not acquired for the purpose of changing control.
• Management of Abivax S.A.: May need to engage with the new significant shareholders regarding their investment strategy.
• Potential Investors: The increased institutional ownership might signal increased interest and stability in the company.

Next Steps

• The reporting persons will continue to monitor their investment in Abivax S.A.
• Future filings may be made if there are changes in beneficial ownership.

Key Dates

Recommendation

The filing indicates a significant investment by established entities, suggesting a positive outlook on Abivax S.A.'s long-term prospects. However, as this is a disclosure of ownership and not an operational update, it does not provide sufficient new information to warrant a buy or sell recommendation. A 'hold' reflects the current neutral stance based on ownership changes without fundamental performance data.

Keywords

Abivax S.A., Schedule 13G, Invus Group, Raymond Debbane, Beneficial Ownership, Ordinary Shares, American Depositary Shares, Investment